Loading…
Pharmacological treatment of actinic keratosis
Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment op...
Saved in:
Published in: | Przegląd dermatologiczny 2016-01, Vol.4 (4), p.330-336 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | eng ; pol |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653 |
---|---|
cites | |
container_end_page | 336 |
container_issue | 4 |
container_start_page | 330 |
container_title | Przegląd dermatologiczny |
container_volume | 4 |
creator | Zwierzyńska, Ewa Zawistowska, Anna Pietrzak, Bogusława |
description | Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated. |
doi_str_mv | 10.5114/dr.2016.61784 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a146cc97b02c41d7a805dca8277a1636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a146cc97b02c41d7a805dca8277a1636</doaj_id><sourcerecordid>4179545001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653</originalsourceid><addsrcrecordid>eNo9kElLA0EQRhtRMEaP3gc8z9j7cpTgEgjoQc9NTS9x4iQduzsH_71ZRCj4oPh4VTyEbgnuBCH83ueOYiI7SZTmZ2hCseat0YadownGjLVUUHmJrkpZYSwNJXSCurdPyGtwaUzLwcHY1BygrsOmNik24OqwGVzzFTLUVIZyjS4ijCXc_OUUfTw9vs9e2sXr83z2sGgdw7i2zAfeS2WcV8QFEaOnQe9HBM_7XnEjJEgswCtMI45ORcFjz7gwkXgjBZui-YnrE6zsNg9ryD82wWCPi5SXFnId3BgsEC6dM6rH1HHiFWgsvANNlQIimdyz7k6sbU7fu1CqXaVd3uzft0QTLZUQiu1b7anlciolh_h_lWB70Gt9tge99qiX_QK5qmxB</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1818675573</pqid></control><display><type>article</type><title>Pharmacological treatment of actinic keratosis</title><source>Publicly Available Content (ProQuest)</source><creator>Zwierzyńska, Ewa ; Zawistowska, Anna ; Pietrzak, Bogusława</creator><creatorcontrib>Zwierzyńska, Ewa ; Zawistowska, Anna ; Pietrzak, Bogusława</creatorcontrib><description>Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.</description><identifier>ISSN: 0033-2526</identifier><identifier>EISSN: 2084-9893</identifier><identifier>DOI: 10.5114/dr.2016.61784</identifier><language>eng ; pol</language><publisher>Poznan: Termedia Publishing House</publisher><subject>actinic keratosis ; clinical studies ; pharmacotherapy</subject><ispartof>Przegląd dermatologiczny, 2016-01, Vol.4 (4), p.330-336</ispartof><rights>Copyright Termedia Publishing House 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1818675573?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25731,27901,27902,36989,44566</link.rule.ids></links><search><creatorcontrib>Zwierzyńska, Ewa</creatorcontrib><creatorcontrib>Zawistowska, Anna</creatorcontrib><creatorcontrib>Pietrzak, Bogusława</creatorcontrib><title>Pharmacological treatment of actinic keratosis</title><title>Przegląd dermatologiczny</title><description>Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.</description><subject>actinic keratosis</subject><subject>clinical studies</subject><subject>pharmacotherapy</subject><issn>0033-2526</issn><issn>2084-9893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNo9kElLA0EQRhtRMEaP3gc8z9j7cpTgEgjoQc9NTS9x4iQduzsH_71ZRCj4oPh4VTyEbgnuBCH83ueOYiI7SZTmZ2hCseat0YadownGjLVUUHmJrkpZYSwNJXSCurdPyGtwaUzLwcHY1BygrsOmNik24OqwGVzzFTLUVIZyjS4ijCXc_OUUfTw9vs9e2sXr83z2sGgdw7i2zAfeS2WcV8QFEaOnQe9HBM_7XnEjJEgswCtMI45ORcFjz7gwkXgjBZui-YnrE6zsNg9ryD82wWCPi5SXFnId3BgsEC6dM6rH1HHiFWgsvANNlQIimdyz7k6sbU7fu1CqXaVd3uzft0QTLZUQiu1b7anlciolh_h_lWB70Gt9tge99qiX_QK5qmxB</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Zwierzyńska, Ewa</creator><creator>Zawistowska, Anna</creator><creator>Pietrzak, Bogusława</creator><general>Termedia Publishing House</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>DOA</scope></search><sort><creationdate>20160101</creationdate><title>Pharmacological treatment of actinic keratosis</title><author>Zwierzyńska, Ewa ; Zawistowska, Anna ; Pietrzak, Bogusława</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; pol</language><creationdate>2016</creationdate><topic>actinic keratosis</topic><topic>clinical studies</topic><topic>pharmacotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zwierzyńska, Ewa</creatorcontrib><creatorcontrib>Zawistowska, Anna</creatorcontrib><creatorcontrib>Pietrzak, Bogusława</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Przegląd dermatologiczny</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zwierzyńska, Ewa</au><au>Zawistowska, Anna</au><au>Pietrzak, Bogusława</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological treatment of actinic keratosis</atitle><jtitle>Przegląd dermatologiczny</jtitle><date>2016-01-01</date><risdate>2016</risdate><volume>4</volume><issue>4</issue><spage>330</spage><epage>336</epage><pages>330-336</pages><issn>0033-2526</issn><eissn>2084-9893</eissn><abstract>Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.</abstract><cop>Poznan</cop><pub>Termedia Publishing House</pub><doi>10.5114/dr.2016.61784</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-2526 |
ispartof | Przegląd dermatologiczny, 2016-01, Vol.4 (4), p.330-336 |
issn | 0033-2526 2084-9893 |
language | eng ; pol |
recordid | cdi_doaj_primary_oai_doaj_org_article_a146cc97b02c41d7a805dca8277a1636 |
source | Publicly Available Content (ProQuest) |
subjects | actinic keratosis clinical studies pharmacotherapy |
title | Pharmacological treatment of actinic keratosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T02%3A37%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20treatment%20of%20actinic%20keratosis&rft.jtitle=Przegla%CC%A8d%20dermatologiczny&rft.au=Zwierzy%C5%84ska,%20Ewa&rft.date=2016-01-01&rft.volume=4&rft.issue=4&rft.spage=330&rft.epage=336&rft.pages=330-336&rft.issn=0033-2526&rft.eissn=2084-9893&rft_id=info:doi/10.5114/dr.2016.61784&rft_dat=%3Cproquest_doaj_%3E4179545001%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1818675573&rft_id=info:pmid/&rfr_iscdi=true |